{{Rsnum
|rsid=4148945
|Gene=CHST3
|Chromosome=10
|position=73769590
|Orientation=plus
|GMAF=0.2686
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 24.8 | 50.4 | 24.8
| HCB | 81.0 | 18.2 | 0.7
| JPT | 75.2 | 23.0 | 1.8
| YRI | 91.8 | 8.2 | 0.0
| ASW | 70.2 | 21.1 | 8.8
| CHB | 81.0 | 18.2 | 0.7
| CHD | 85.0 | 14.0 | 0.9
| GIH | 46.5 | 38.6 | 14.9
| LWK | 85.3 | 12.8 | 1.8
| MEX | 39.7 | 44.8 | 15.5
| MKK | 83.3 | 15.4 | 1.3
| TSI | 28.4 | 47.1 | 24.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4148945
|Name_s=CHST3:rs4148945 C>T; NM_004273.3:c.*1361C>T
|Gene_s=CHST3
|Feature=3' UTR
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: C Phenotype: The CHST3:rs4148945 C variant was associated with positive clincial response (partial or complete response) to treatment and toxicity to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.011 (response); p = 0.010 (TOX) Type of association: PD; CO; TOX
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111534
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4148945
|overall_frequency_n=37
|overall_frequency_d=128
|overall_frequency=0.289062
|n_genomes=25
|n_genomes_annotated=0
|n_haplomes=34
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}